Intranasal Bevacizumab for HHT-Related Epistaxis

NCT02389959 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

HHT
Hereditary Hemorrhagic Telangiectasia
Epistaxis
Nose Bleeds
Nasal Bleeding

Interventions

DRUG: Bevacizumab
DRUG: Placebo (Saline)

Sponsor

Stanford University